株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

米国の肥満治療薬・装置市場

U.S. Markets for Obesity Drugs & Devices

発行 Medtech Insight 商品コード 143932
出版日 ページ情報 英文 176 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
米国の肥満治療薬・装置市場 U.S. Markets for Obesity Drugs & Devices
出版日: 2015年02月27日 ページ情報: 英文 176 Pages
概要

National Health and Nutrition Examination Survey (NHANES) によると、2012年において、米国における20歳以上の成人の約35%、もしくは約3分の1が、BMI (ボディマス指数) 30kg/平方メートル以上の肥満と分類されました。これは数にして1億人以上の肥満人口に換算されます。2014年において、米国の「新興の」肥満治療薬および (低侵襲性医療) 装置市場規模の合計は約3億7,470万米ドルと推計されています。予測期間を通して、市場は複利年率32.4%と二桁の安定した成長が予測され、規模は2015年の4億5,540万米ドルから、2020年には18億5,210万米ドルに拡大すると見込まれています。

当レポートは、米国の肥満治療薬・装置市場の動向を分析し、主な治療薬市場の分析、製品タイプ別の市場分析、および新興の医療装置技術の分析を提供しています。

エグゼクティブサマリー

第1章 肥満治療薬

  • 主要な肥満治療薬
    • Genentech/Roche Group (Xenical)
    • Vivus (Qsymia)
    • Arena Pharmaceuticals/Eisai (Belviq)
    • Orexigen Therapeutics/Takeda (Contrave)
  • 新興の肥満治療薬
    • Gelesis (Gelesis100)
    • Hanmi Pharmaceuticals (LAPS CA-Exendin-4/HPP4404)
    • Novo Nordisk (Saxenda)
    • Orexigen Therapeutics (Empatic)
    • Rhythm Pharmaceuticals (RM-493)
    • Zafgen (Beloranib)
  • 市場分析
    • 市場予測
    • 競合分析

第2章 腹腔鏡下調節性胃バンディング装置 (LAGB装置)

  • 主なLAGBシステム
    • Apollo Endosurgery
    • Ethicon Endo-Surgery/Johnson & Johnson
    • その他のLAGB装置
  • 市場分析
    • 手術数の予測
    • 市場予測
    • 競合分析

第3章 胃内バルーン装置

  • Apollo Endosurgery
  • Helioscopie
  • ReShape Medical
  • Spatz FGIA
  • Obalon Therapeutics
  • 市場分析

第4章 植込み型迷走神経遮断療法

  • EnteroMedics
  • MetaCure
  • 市場分析

第5章 その他の新興医療装置技術

  • Aspire Bariatrics
  • BAROnova
  • EndoSphere, Inc.
  • GI Dynamics
  • Onciomed
  • Scientific Intake
  • TransEnterix
  • USGI Medical
  • その他

米国の総肥満治療薬・装置市場

  • 新興肥満治療薬市場
  • 肥満治療装置市場

付録:企業リスト

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: A153

According to National Health and Nutrition Examination Survey (NHANES), approximately 35%, or nearly one out of three adults age 20 years or older were classified as obese in 2012 (the latest available statistics) based on a BMI of 30 kg/m2 or greater. This translates to more than 100 million obese people in the U.S.- a staggering number. Obesity has become such as concern due to increasing prevalence and the rise of serious health-related co-morbidities, such as type 2 diabetes, that it has recently been recognized by the American Medical Association, as well as other medical and government organizations, as a chronic disease. Due to the fact that type 2 diabetes and obesity are closely linked, the rise of obesity is increasing the prevalence of diabetes, making it critical to develop improved medical treatments to more effectively treat both conditions.

The fact that the overweight, obese and morbidly obese population remains vastly undertreated (in the U.S. and worldwide) bodes very well for next-generation obesity drugs and devices, as it leaves significant room for companies to profit and grow revenues in the coming decade in a virtually untapped U.S. market, expected to be valued at more than $1.8 billion by the year 2020.

This dynamic, new report from Medtech Insight includes analyses of selected products, current/forecast markets, surgical procedure volumes, competitors, market share by supplier, and opportunities in the U.S. Obesity Drugs and Devices Market. Specifically, this report covers leading and emerging prescription-based weight loss (obesity) drugs, and minimally invasive medical devices, including: laparoscopic adjustable gastric banding (LAGB) systems, intragastric balloon systems, implantable gastric stimulation devices, and other emerging device-based technologies, including nonsurgical/incisionless, transorally inserted or next-generation minimally invasive weight loss device therapies.

In 2014, the total, combined U.S. market for “new” obesity drugs and (minimally invasive medical) devices for the treatment of obesity was estimated at approximately $374.7 million. Over the forecast period, the total market is expected to advance at a healthy, double-digit compound annual rate of 32.4%, from an estimated $455.4 million in 2015 to an estimated $1,852.1 million in the year 2020.

Table of Contents

EXECUTIVE SUMMARY

  • i. U.S. Obesity Drugs & Devices Market
  • ii. Methodology
  • Exhibit ES-1: U.S. Obesity Drugs & Devices Market, 2013-2020

1. OBESITY DRUGS

  • 1.1. Leading Obesity Drugs
    • 1.1.1. Genentech/Roche Group (Xenical)
    • 1.1.2. Vivus (Qsymia)
    • 1.1.3. Arena Pharmaceuticals/Eisai (Belviq)
    • 1.1.4. Orexigen Therapeutics/Takeda (Contrave)
  • 1.2. Emerging Obesity Drugs
    • 1.2.1. Gelesis (Gelesis100)
    • 1.2.2. Hanmi Pharmaceuticals (LAPS CA-Exendin-4/HPP4404)
    • 1.2.3. Novo Nordisk (Saxenda)
      • 1.2.3.1. Victoza (liraglutide)
    • 1.2.4. Orexigen Therapeutics (Empatic)
    • 1.2.5. Rhythm Pharmaceuticals (RM-493)
    • 1.2.6. Zafgen (Beloranib)
  • 1.3. Market Analysis
    • 1.3.1. Market Forecast
      • 1.3.1.1. Market Drivers
      • 1.3.1.2. Market Limiters
    • 1.3.2. Competitive Analysis
  • Exhibit 1-1: 2015, FDA Approved Obesity Drugs
  • Exhibit 1-2: Xenical, SWOT Analysis
  • Exhibit 1-3: Qsymia, SWOT Analysis
  • Exhibit 1-4: Belviq, SWOT Analysis
  • Exhibit 1-5: Contrave, SWOT Analysis
  • Exhibit 1-6: 2015, Selected Obesity Drugs Recently FDA Approved or Under Development
  • Exhibit 1-7: Gelesis100 Mechanism of Action
  • Exhibit 1-8: New Obesity Drugs, Market Forecast, 2013-2020
  • Exhibit 1-9: 2013, New Obesity Drugs Market, Share by Supplier
  • Exhibit 1-10: 2014, New Obesity Drugs Market, Share by Supplier

2. LAPAROSCOPIC ADJUSTABLE GASTRIC BANDING SYSTEMS

  • 2.1. Leading LAGB Systems
    • 2.1.1. Apollo Endosurgery
    • 2.1.2. Ethicon Endo-Surgery/Johnson & Johnson
    • 2.1.3. Other LAGB Systems (Available Outside the U.S.)
      • 2.1.3.1. Agency for Medical Innovations
      • 2.1.3.2. Cousin Biotech
      • 2.1.3.3. Hélioscopie
      • 2.1.3.4. Médical Innovation Développement
  • 2.2. Market Analysis
    • 2.2.1. Procedure Volumes Forecast
    • 2.2.2. Market Forecast
      • 2.2.2.1. Market Drivers
      • 2.2.3.2. Market Limiters
    • 2.2.3. Competitive Analysis
  • Exhibit 2-1: Risks Associated with Gastric Banding and Abdominal/Bariatric Surgery
  • Exhibit 2-2: 2015, Laparoscopic Adjustable Gastric Banding Systems
  • Exhibit 2-3: Apollo EndoSurgery's LAP-BAND
  • Exhibit 2-4: Key Benefits and Risks of the LAP-BAND Procedure
  • Exhibit 2-5: Excess Weight Loss with the LAP-BAND System Compared to Roux-en-Y Gastric Bypass at 3 Years and Beyond
  • Exhibit 2-6: Ethicon Endo-Surgery's Curved Adjustable Gastric Endo Band, Features and Benefits
  • Exhibit 2-7: Comparison of Gastric Banding, Gastric Bypass, and Sleeve Gastrectomy
  • Exhibit 2-8: Agency for Medical Innovations'Soft Gastric Band Premium
  • Exhibit 2-9: Cousin Biotech's Bioring Adjustable Gastric Band
  • Exhibit 2-10: Hélioscopie's Heliogast HAGA Adjustable Gastric Band
  • Exhibit 2-11: Médical Innovation Développement's MIDBAND Adjustable Gastric Band
  • Exhibit 2-12: Laparoscopic Adjustable Gastric Banding, Procedure Volumes Forecast, 2013-2020
  • Exhibit 2-13: Estimated Number of Bariatric Surgeries, U.S. Procedure Volumes Forecast, 2013-2020
  • Exhibit 2-14: 2015 and 2020, Comparison of Estimated Bariatric Surgical Volumes, by Percentage and Type of Surgery
  • Exhibit 2-15: Laparoscopic Adjustable Gastric Banding, Market Forecast, 2013-2020
  • Exhibit 2-16: 2013, Laparoscopic Adjustable Gastric Banding Systems, Share by Supplier
  • Exhibit 2-17: 2014, Laparoscopic Adjustable Gastric Banding Systems Market, Share by Supplier

3. INTRAGASTRIC BALLOON SYSTEMS

  • 3.1. Apollo Endosurgery
  • 3.2. Hélioscopie
  • 3.3. ReShape Medical
  • 3.4. Spatz FGIA
  • 3.5. Obalon Therapeutics
  • 3.6. Market Analysis
    • 3.6.1. Market Drivers
    • 3.6.2. Market Limiters
  • Exhibit 3-1: Apollo Endosurgery's Orbera Managed Weight Loss System
  • Exhibit 3-2: Hélioscopie's Heliosphere Intragastric Balloon
  • Exhibit 3-3: ReShape Duo Intragastric Balloon System
  • Exhibit 3-4: REDUCE Pivotal Trial Results
  • Exhibit 3-5: The Spatz Adjustable Balloon System
  • Exhibit 3-6: Risks of Intragastric Balloon Placement
  • Exhibit 3-7: The Spatz Adjustable Balloon Procedure
  • Exhibit 3-8: The Obalon Gastric Balloon System Features and Possible Complications
  • Exhibit 3-9: Intragastric Balloon Therapy, Procedure Volumes Forecast, 2015-2020
  • Exhibit 3-10: Intragastric Balloon Systems, Market Forecast, 2015-2020

4. IMPLANTABLE VAGAL BLOCKING THERAPY

  • 4.1. EnteroMedics
  • 4.2. MetaCure
  • 4.3. Market Analysis
    • 4.3.1. Market Drivers
    • 4.3.2. Market Limiters
  • Exhibit 4-1: 2015, Implantable Pulse Generators Developed for the of Obesity
  • Exhibit 4-2: EnteroMedics' Maestro System
  • Exhibit 4-3: Overview of EnteroMedics' VBLOC Therapy and Vagus Nerve Function
  • Exhibit 4-4: Potential Benefits and Risks of VBLOC Therapy
  • Exhibit 4-5: Comparison of VBLOC Therapy, Laparoscopic Banding, and Gastric Bypass
  • Exhibit 4-6: MetaCure's DIAMOND (TANTALUS) Gastric Stimulation System
  • Exhibit 4-7: Implantable VBLOC Therapy Devices, EnteroMedics,Procedure Volumes Forecast, 2015-2020
  • Exhibit 4-8: Implantable VBLOC Therapy Devices, EnteroMedics, Market Forecast, 2015-2020

5. OTHER EMERGING MEDICAL DEVICE TECHNOLOGIES

  • 5.1. Aspire Bariatrics
  • 5.2. BAROnova
  • 5.3. EndoSphere, Inc.
  • 5.4. GI Dynamics
  • 5.5. Onciomed
  • 5.6. Scientific Intake
  • 5.7. TransEnterix
  • 5.9. USGI Medical
  • 5.9. Others
  • Exhibit 5-1: 2015, Selected Emerging Medical Device Technologies for the Treatment of Obesity
  • Exhibit 5-2: Aspire Bariatric's AspireAssist
  • Exhibit 5-3: EndoSphere's SatiSphere
  • Exhibit 5-4: GI Dynamic's EndoBarrier Gastrointestinal Liner and Procedure
  • Exhibit 5-5: Scientific Intake's SMART Device
  • Exhibit 5-6: USGI Medical's Incisionless Operating Platform
  • Exhibit 5-7: Primary Obesity Surgery, Endolumenal

TOTAL U.S. OBESITY DRUGS AND DEVICES MARKET

  • i. New Obesity Drugs Market
  • ii. Obesity Devices Market
  • Exhibit 6-1: U.S. Obesity Drugs & Devices Market, 2013-2020
  • Exhibit 6-2: U.S. New Obesity Drugs Market, 2013-2020
  • Exhibit 6-3: U.S. Obesity Devices Market, 2013-2020

APPENDIX: COMPANY LISTING

Back to Top